Cargando…
A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
A 54‐year‐old woman presented to our hospital with a fever and cough. The patient had a medical history of follicular lymphoma treated with obinutuzumab. She was infected with an omicron variant of coronavirus disease 2019 and developed viral pneumonia. Antibiotics, molnupiravir, sotrovimab, and pre...
Autores principales: | Shimizu, Takahiro, Shirasaki, Hiroki, Okafuji, Kazuhiro, Sawazaki, Aiko, Iwabuchi, Tasuku, Matubayashi, Ryo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912017/ https://www.ncbi.nlm.nih.gov/pubmed/36789174 http://dx.doi.org/10.1002/rcr2.1099 |
Ejemplares similares
-
Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022) -
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022) -
498. Covid-19 Hospitalization Rates in Kidney Transplant Patients Treated with Tixagevimab/Cilgavimab
por: Dugan, Katherine, et al.
Publicado: (2023) -
Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)